QL Biopharm is a biopharmaceutical company developing innovative peptide and protein drugs. Its proprietary platforms use synthetic biology and protein engineering to create long-acting, highly active therapeutics. Its pipeline addresses major diseases including metabolic disorders. Core GLP-1 weight-loss and glucose-lowering drugs have entered Phase II and Phase III studies respectively, advancing innovative biologic development and clinical translation
We have received your business plan. After completing an initial evaluation, our investment team will contact projects that align with our investment focus. Due to the volume of submissions, we appreciate your understanding if you do not receive a follow-up. We wish your project every success!
OK
This website uses cookies
This website uses cookies to improve your experience while you navigate through the website. You
can choose to opt-out if you wish. For more information, please refer to our
《Cookies》。